Key Highlights

  • Iambic (NASDAQ:IAM) reported third-quarter collaboration Revenue of USD 11.4 million, up from USD 4.7 million a year earlier, and a net loss of USD 38.5 million against USD 21.5 million.
  • Research and development expenses rose to USD 34.1 million from USD 23.1 million, while general and administrative expenses climbed to USD 7.4 million from USD 4.3 million.
  • Cash and cash equivalents were about USD 252 million at September 30, 2026, and about USD 455 million pro forma for IPO net proceeds and AbbVie upfront payments received in October.
  • The October IPO sold 10,781,250 shares at USD 16.00 each for gross proceeds of USD 172.5 million, with trading on the Nasdaq Global Select Market starting October 15, 2026.

Partnership Revenue More Than Doubles While Costs Climb

Iambic (NASDAQ:IAM) is a San Diego clinical-stage company that pairs an AI-driven platform with automated chemistry and biology experiments to design new medicines. Its third-quarter report, dated November 16, 2026, shows collaboration revenue of USD 11.4 million, up from USD 4.7 million, which is a calculated rise of about 141.9%. The company ties the increase mainly to its discovery collaborations.

Research and development expense reached USD 34.1 million, a calculated increase of about 47.9%, on higher clinical and Manufacturing costs, a growing discovery pipeline and added headcount. General and administrative expense of USD 7.4 million, a calculated rise of about 73.0%, reflected headcount growth and public company readiness. Net loss was USD 38.5 million and included a USD 10.4 million non-cash charge from the change in Fair Value of convertible notes, which converted into common stock just before the IPO closed.

Collaboration Billings and Cash Outlook After the IPO

Management highlighted that, through the third quarter, billings from collaborations were about USD 100 million, against about USD 24 million of collaboration revenue and about USD 108 million of total operating expenses. Billings are a non-GAAP measure defined as collaboration revenue plus the change in deferred revenue.

Cash and cash equivalents stood at USD 252 million on September 30, 2026. That excludes about USD 156 million of IPO net proceeds and USD 47 million of AbbVie upfront payments, both received in October, which brings pro forma cash to about USD 455 million. The company says it expects Research and Development costs to increase as Clinical Trials expand.

IAM1363 Data, New INDs and Eight Partnerships Define the Pipeline

At the ESMO 2026 meeting, Iambic presented data on IAM1363, a brain-penetrant HER2 inhibitor, showing partial responses in 36% of 53 evaluable heavily pretreated patients systemically and in 41% of 22 evaluable patients intracranially, as of an August 31, 2026 cutoff. Among 68 patients dosed at 960 mg once daily, 5.9% had a grade 3 treatment-related adverse event and none had grade 4 or 5. A registrational study in HER2-positive breast cancer is planned for 2027, subject to FDA approval.

The company submitted an IND for IAM217, a KIF18A inhibitor, on September 30, 2026 and received a Safe-to-Proceed Letter from the FDA for a Phase 1/2 trial. An IND for IAM-C1, a CDK2/4 inhibitor, is expected in the fourth quarter of 2026. New collaborations were signed with Bayer in June and AbbVie in September, and a Takeda program milestone triggered a USD 1.0 million payment, bringing the total to eight partnerships since 2024.

Where Things Stand

Revenue is growing quickly, but so are losses. Iambic (NASDAQ:IAM) turned Partnership income into USD 11.4 million of quarterly revenue while spending USD 41.5 million on operations, and the IPO plus AbbVie payments lift pro forma cash to about USD 455 million. Watch for the IAM-C1 IND in the fourth quarter, preclinical data at the EORTC-NCI-AACR Symposium on November 18 to 20, 2026, the move to a 121,000-square-foot headquarters this month, and registrational plans for IAM1363 in 2027.